Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp (UTHR) reported insider activity by Chairperson & CEO Martine A. Rothblatt through family trusts. On 2026-08-27, a trust exercised 9,500 stock options at an exercise price of $135.42 per share into an equal number of common shares, then sold 9,500 common shares in multiple open-market transactions at weighted-average prices generally between about $511 and $531 per share. The option exercise and related sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, a family trust continued to hold 46,910 stock options with a $135.42 exercise price, while reported common stock holdings included 40,513 shares held directly and 166 shares held indirectly by a spouse, with additional indirect holdings through family trusts.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $135.42 per share and acquired an equal number of shares on August 26, 2026. Those 9,500 shares were then sold the same day in multiple open-market transactions by a family trust at weighted-average prices in the $514–$521 range, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the option exercise, a family trust continued to hold 56,410 stock options expiring March 15, 2027, and separate entries show direct ownership of 40,513 UTHR shares and additional indirect holdings, including 166 shares held by a spouse.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $135.42 per share and acquired 9,500 common shares on August 25, 2026. The same day, those 9,500 indirectly held shares were sold in multiple open-market transactions at weighted average prices between $515.46 and $520.52 per share. After the option exercise, a family trust held 65,910 stock options, and separately, Rothblatt held 40,513 common shares directly and 166 shares indirectly through a spouse. These option exercises and related sales were made under a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026.
UNITED THERAPEUTICS Corp (UTHR) reported that family trusts associated with Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share into common stock and sold 9,500 common shares on August 24, 2026 in multiple trades at weighted-average prices around $509–$513 per share. The options transaction reduced the trust’s stock option position to 75,410 options. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026. Separately, Rothblatt reports 40,513 UTHR common shares held directly and 166 shares held indirectly by spouse.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share and acquired 9,500 shares of common stock on August 21, 2026. On the same date, those 9,500 common shares were sold in multiple trades at weighted-average prices, with individual trades executed in ranges from $512.51 to $528.02 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the option exercise, a family trust held 84,910 stock options, while reported direct common stock holdings were 40,513 shares, with additional indirect holdings by spouse and family trusts.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 per share into common stock and sold 9,500 common shares on August 20, 2026 at weighted average prices around $518–$525. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the option exercise, the trust holds 94,410 stock options from this grant, while Rothblatt also reports 40,513 common shares held directly and 166 shares held indirectly by spouse, with additional indirect holdings in family trusts.
UNITED THERAPEUTICS Corp (UTHR) reported that EVP & General Counsel Paul A. Mahon exercised stock options for 8,300 shares of common stock at an exercise price of $146.03 per share on August 20, 2026, and sold 8,300 shares in multiple open-market trades at prices between approximately $520.03 and $527.21. The options exercise and resulting share sales were carried out under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025.
UNITED THERAPEUTICS CORPORATION (UTHR) has a notice under Rule 144 indicating that officer Paul Mahon may sell 8,300 shares of common stock, expected to be issued from a stock option exercise on 08/20/2026, through Morgan Stanley Smith Barney LLC. The notice also lists a series of sales by Mahon over the prior three months, each for 8,300 shares of common stock at various total sale values.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share, receiving 9,500 shares of common stock, and on the same date sold 9,500 shares in multiple open-market transactions at prices around $522–$536 per share.
After the option exercise, a family trust held 103,910 stock options. Additional holdings reported include 40,513 shares held directly and 166 shares held indirectly by spouse. All option exercises and related sales were made under a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring March 15, 2027, or December 31, 2026.
UNITED THERAPEUTICS Corp (UTHR) Chairperson & CEO Martine Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share into 9,500 shares of common stock on August 18, 2026, then sold 9,500 shares in multiple open-market trades at weighted average prices around the low-$500s per share. After the option exercise, the family trust held 113,410 stock options, and Rothblatt also reported 40,513 shares held directly and 166 shares held indirectly by spouse. All option exercises and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which covers up to 1,734,410 options expiring March 15, 2027, or runs until December 31, 2026.